Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.

Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D.

Int J Hematol. 2014 Jan;99(1):91-4. doi: 10.1007/s12185-013-1474-x. Epub 2013 Nov 22.

PMID:
24264834
2.

Management of the new patient with CML in chronic phase.

Marin D.

Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0. Review.

PMID:
23381448
3.

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.

Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC.

Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22.

PMID:
23433665
4.

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A.

Blood. 2014 Jan 23;123(4):494-500. doi: 10.1182/blood-2013-06-511592. Epub 2013 Dec 5.

5.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

Wei G, Rafiyath S, Liu D.

J Hematol Oncol. 2010 Nov 26;3:47. doi: 10.1186/1756-8722-3-47. Review.

6.

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.

Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S.

Int J Hematol. 2014 Feb;99(2):141-53. doi: 10.1007/s12185-013-1470-1. Epub 2013 Dec 20.

PMID:
24357015
7.

Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.

Quintás-Cardama A, Jabbour EJ.

Leuk Res. 2013 May;37(5):487-95. doi: 10.1016/j.leukres.2013.01.006. Epub 2013 Feb 4. Review.

PMID:
23391518
8.

Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.

Zonder JA, Schiffer CA.

Curr Hematol Malig Rep. 2006 Sep;1(3):141-51. doi: 10.1007/s11899-996-0002-y. Review.

PMID:
20425345
9.

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

Jabbour E, Kantarjian H, Cortes J.

Semin Hematol. 2010 Oct;47(4):344-53. doi: 10.1053/j.seminhematol.2010.06.002. Review.

PMID:
20875551
10.
11.

Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.

Whiteley J, Iyer S, Candrilli SD, Kaye JA.

Curr Med Res Opin. 2015 Feb;31(2):299-314. doi: 10.1185/03007995.2014.991817. Epub 2015 Jan 30.

PMID:
25427232
12.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.

Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.

PMID:
18401416
13.

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.

Jabbour E, Kantarjian H.

Am J Hematol. 2012 Nov;87(11):1037-45. doi: 10.1002/ajh.23282. Review.

14.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M.

Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.

15.

Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.

Li J, Xu G, Yu S, He L, Guo L.

J Int Med Res. 2011;39(2):337-47.

PMID:
21672337
16.

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.

Barańska M, Lewandowski K, Gniot M, Iwoła M, Lewandowska M, Komarnicki M.

J Appl Genet. 2008;49(2):201-3. doi: 10.1007/BF03195613.

PMID:
18436994
17.

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Stein B, Smith BD.

Clin Ther. 2010 May;32(5):804-20. doi: 10.1016/j.clinthera.2010.05.003. Review.

18.

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.

Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW.

Leuk Lymphoma. 2014 Sep;55(9):2093-100. doi: 10.3109/10428194.2013.866663. Epub 2014 Mar 12.

19.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.

Blood. 2007 Mar 15;109(6):2303-9. Epub 2006 Nov 30. Erratum in: Blood. 2007 Sep 1;110(5):1438.

20.

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.

Kantarjian HM, Cortes J, La Rosée P, Hochhaus A.

Cancer. 2010 Mar 15;116(6):1419-30. doi: 10.1002/cncr.24928. Review.

Supplemental Content

Support Center